Amphastar Pharmaceuticals (AMPH) Assets Average (2014 - 2026)

Amphastar Pharmaceuticals has reported Assets Average for 13 years, with the latest figure at $1.7 billion in Q2 2026.

• On a quarterly basis, Assets Average rose 4.64% year-over-year to $1.7 billion in Q2 2026; TTM through Jun 2026 was $1.7 billion, a 4.64% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 3.77% from the prior year.
• Assets Average was $1.7 billion for Q2 2026 at Amphastar Pharmaceuticals, up from $1.6 billion in the prior quarter.
• The five-year high for Assets Average was $1.7 billion in Q2 2026, with the low at $693.9 million in Q1 2022.
• Average Assets Average over 5 years is $1.3 billion, with a median of $1.5 billion recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Assets Average soared 108.18% in 2023, then grew 2.13% in 2024.
• Over 5 years, Assets Average stood at $734.3 million in 2022, then jumped by 108.18% to $1.5 billion in 2023, then rose by 2.13% to $1.6 billion in 2024, then grew by 5.54% to $1.6 billion in 2025, then rose by 2.93% to $1.7 billion in 2026.
• The last three Assets Average figures came in at $1.7 billion (Q2 2026), $1.6 billion (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.